Scancell appoints Dr Ursula Ney to its Board as Non-Executive Director

– UK, Nottingham –  Scancell Holdings plc, (LON: SCLP), the developer of novel immunotherapies for the treatment of cancer, today announced the appointment of Dr Ursula Ney as a Non-Executive Director of the Company with immediate effect, replacing Dr Matthew Frohn who is standing down on 31 October 2019 after more than twelve years of service to the Company.

“I am pleased to welcome Ursula to the Board of Scancell. Ursula’s extensive late-stage development experience in the biotech sector will be invaluable as the Company continues to develop its product pipeline. I’d also like to take this opportunity to thank Matthew Frohn for the invaluable contributions he has made to the Company since he was first appointed to the Board in 2006. We wish him well in his future endeavours.” said Dr John Chiplin Chairman of Scancell.

About Dr Ursula Ney

Dr Ney has over thirty years’ experience in the pharmaceutical and biotechnology industry, including twenty years in senior leadership roles that also encompassed Executive and Non-Executive Board positions. She has broad experience of biologic and small molecule drug development across a range of therapeutic areas having been Director of Drug Development and on the Board of Celltech plc and later Chief Operating Officer and Executive Director of Antisoma plc. Most recently, she was Chief Executive Officer of Genkyotex SA. She was on the Board of Discuva Ltd and is currently also a Non-Executive Director of Proteome Sciences plc.

Dr Ursula Ney commented: “I am delighted to be joining the Scancell Board at this exciting time and look forward to working with the team in realising the potential of the ImmunoBody, Moditope and AvidiMab platforms.”

Dr Ney’s early career was spent at Sandoz and Roche. She has a PhD from the Royal Free Hospital Medical School and an MBA from Middlesex University Business School.

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer-based on its ImmunoBody and Moditope technology platforms.

ImmunoBody vaccines target dendritic cells and stimulate both parts of the cellular immune system. They have the potential to be used as monotherapy or in combination with checkpoint inhibitors and other agents. This platform has the potential to enhance tumour destruction, prevent disease recurrence and extend survival.

SCIB1, the lead programme, is being developed for the treatment of melanoma. A phase 1/2 clinical trial has so far successfully demonstrated survival data of more than five years.

SCIB2 is being developed for the treatment of non-small cell lung cancer and other solid tumours. Scancell has entered into a clinical development partnership with Cancer Research UK for SCIB2.

Moditope represents a completely new class of potent and selective immunotherapy agents based on stress-induced post-translational modifications. It stimulates the production of killer CD4 T cells which overcome the immune suppression induced by tumours, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Moditope alone, or in combination with other agents, has the potential to treat a wide variety of cancers.

Modi-1 is being developed for the treatment of solid tumours including triple-negative breast cancer, ovarian cancer and head and neck cancer.

AvidiMab is a patent-protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification induces the direct tumour cell killing properties of Scancell’s anti-glycan monoclonal antibodies but has broad potential to increase the avidity or potency of any therapeutic monoclonal antibody including those being developed for autoimmune diseases, as well as cancer.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.